• Sino Biopharmaceutical launched SBP Group as a unified global brand, repositioning the company for international expansion.
• Strategy shifts toward product globalization via in-house R&D, acquisitions, partnerships, direct commercial buildout in key overseas markets.
• Management cited four out-licensing deals with multinationals, topping USD 1 billion in upfront payments, over USD 7 billion potential value.
• 2026 transactions highlighted licensing rovadicitinib to Sanofi for up to USD 1.53 billion, TQC3721 to AstraZeneca for up to USD 1.9 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608190727PR_NEWS_USPR_____CN29441) on August 19, 2026, and is solely responsible for the information contained therein.